Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers
Krebs, Matthew G Lopez, J El-Khoueiry, A Bang, Y Postel-Vinay, S Abida, W Carter, Louise Xu, W Im, S Pierce, A
Krebs, Matthew G
Lopez, J
El-Khoueiry, A
Bang, Y
Postel-Vinay, S
Abida, W
Carter, Louise
Xu, W
Im, S
Pierce, A
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Krebs MG, Lopez J, El-Khoueiry A, Bang Y-J, Postel-Vinay S, Abida W, et al. Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers. Cancer Res. 2018;78(13).